UK Yellow Card Reporting for GLP-1-Based Therapies Using Partial NHS Primary Care Prescribing and Hospital Medicine Data from England
Open Access
- 13 October 2026
- journal article
- research article
- Published by MDPI AG in Diabetology
- Vol. 7 (10) , 200
Abstract
Background/Objectives: In this retrospective aggregate pharmacovigilance study, we described UK Yellow Card reporting relative to partial English National Health Service (NHS) general practice (GP) prescribing for six glucagon-like peptide-1 (GLP-1)-based therapies. Methods: Primary overall reaction ratios used matching complete calendar years within each medicine: 2022–2025 for five medicines and 2024–2025 for tirzepatide. UK reaction counts were divided by English NHS GP items; geographical and product-coverage differences remain. Separate medicine estimates used conditional exact Poisson intervals without pooling. Annual models allowed for overdispersion. Outcome-specific extracts with unmatched windows and the combined GP plus estimated hospital denominator were secondary analyses. Results: Under the incomplete English NHS GP denominator, primary reaction ratios per million items were tirzepatide 23,808.48, semaglutide 5720.42, liraglutide 1700.45, exenatide 370.52, dulaglutide 258.11, and lixisenatide 87.70. Overall and severity report-based ratios were available for four medicines over their eligible periods. Temporal estimates were imprecise; tirzepatide had only two complete years, and lixisenatide had three reaction entries in its complete-year series, so neither received trend inference. Conclusions: Calendar matching improves the temporal definition of the overall ratios. Omitted private prescribing, UK–England population differences, uncertain product matching and reporting behaviour still prevent interpretation as incidence or comparative safety.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Online Prescribing of GLP-1 Receptor AgonistsJAMA, 2026
- Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and SuicidalityJAMA Network Open, 2024
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance databaseInternational Journal of Clinical Pharmacy, 2024
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossJAMA, 2023
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary DiseasesJAMA Internal Medicine, 2022
- Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010JAMA, 2017
- A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment CommitteeDrug Safety, 2014
- The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010Drug Safety, 2014
- Timing of New Black Box Warnings and Withdrawals for Prescription MedicationsJAMA, 2002
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998